|Title||Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Mirantes C, Dosil MAlba, Hills D, Yang J, Eritja N, Santacana M, Gatius S, Vilardell F, Medvinsky AL, Matias-Guiu X, Dolcet X|
|Date Published||2016 Apr 14|
|Keywords||Animals, Bone Marrow Cells, Disease Models, Animal, Female, Flow Cytometry, Gene Deletion, Hematopoietic Stem Cells, Integrases, Kaplan-Meier Estimate, Leukocyte Common Antigens, Male, Mice, Mice, Knockout, Myeloproliferative Disorders, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, PTEN Phosphohydrolase|
Since its discovery in the late 1990s, Pten has turned out to be one of the most important tumor suppressor genes. Pten loss results in increased activation of the phosphatidylinositol 3-kinase/Akt signaling pathway, which is associated with increased proliferation, survival, and neoplastic growth. Here, we have addressed the effects of conditional deletion of Pten in hematopoietic cells by crossing Pten conditional knockout mice with a knock-in mouse expressing the Cre recombinase in the CD45 locus. CD45 is also known as leukocyte common antigen, and it is expressed in virtually all white cells and in hematopoietic stem cells. Using a reporter mouse, we demonstrate that CD45:Cre mouse displays recombinase activity in both myeloid and lymphoid cells. However, deletion of Pten in CD45-expressing cells induces development of T-cell acute lymphoblastic leukemia and lymphoma, but not other hematologic malignancies.
|PubMed Central ID||PMC4874386|